Biotechnology in Europe

Introduction

Biotechnology in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Europe biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

*The biotechnology market consists of the development, manufacturing and marketing of products based on advanced biotechnology research. The market value reflects revenues of companies within this industry from product sales, licensing fees, royalties and research funding. Any currency conversions used in the creation of this report have been calculated using constant 2011 annual average exchange rates.

*The European biotechnology market had total revenue of $65,544.7 million in 2010, representing a compound annual growth rate (CAGR) of 10.7% between 2006 and 2010.

*Medical/Healthcare sales proved the most lucrative for the European biotechnology market in 2010, with total revenues of $51,263.1 million, equivalent to 78.2% of the market's overall value.

*The performance of the market is forecast to decelerate, with an anticipated CAGR of 7.4% for the five-year period 2010 - 2015, which is expected to drive the market to a value of $93,831.6 million by the end of 2015.

Features

Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Europe

Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Europe

Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance

Add weight to presentations and pitches by understanding the future growth prospects of the Europe biotechnology market with five year forecasts

Macroeconomic indicators provide insight into general trends within the Europe economy

Key Questions Answered

What was the size of the Europe biotechnology market by value in 2010?

What will be the size of the Europe biotechnology market in 2015?

What factors are affecting the strength of competition in the Europe biotechnology market?

How has the market performed over the last five years?

What are the main segments that make up Europe's biotechnology market?
[Studien Infos ausblenden]

TABLE OF CONTENTS
EXECUTIVE SUMMARY 2
MARKET OVERVIEW 7
Market definition 7
Research highlights 8
Market analysis 9
MARKET VALUE 10
MARKET SEGMENTATION I 11
MARKET SEGMENTATION II 12
FIVE FORCES ANALYSIS 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Substitutes 17
Rivalry 18
LEADING COMPANIES 19
Astra Zeneca 19
Boehringer Ingelheim 23
Merck KGaA 27
Novartis AG 30
MARKET FORECASTS 34
Market value forecast 34
APPENDIX 35
Methodology 35
Industry associations 36
Related Datamonitor research 36
Disclaimer 37
ABOUT DATAMONITOR 38
Premium Reports 38
Summary Reports 38
Datamonitor consulting 38

LIST OF TABLES
Table 1: Europe biotechnology market value: $ million, 2006–10 10
Table 2: Europe biotechnology market segmentation I:% share, by value, 2010 11
Table 3: Europe biotechnology market segmentation II: % share, by value, 2010 12
Table 4: Astra Zeneca: key facts 19
Table 5: Astra Zeneca: key financials ($) 21
Table 6: Astra Zeneca: key financial ratios 21
Table 7: Boehringer Ingelheim : key facts 23
Table 8: Boehringer Ingelheim : key financials ($) 24
Table 9: Boehringer Ingelheim : key financials (€) 25
Table 10: Boehringer Ingelheim : key financial ratios 25
Table 11: Merck KGaA: key facts 27
Table 12: Merck KGaA: key financials ($) 28
Table 13: Merck KGaA: key financials (€) 28
Table 14: Merck KGaA: key financial ratios 28
Table 15: Novartis AG: key facts 30
Table 16: Novartis AG: key financials ($) 31
Table 17: Novartis AG: key financial ratios 32
Table 18: Europe biotechnology market value forecast: $ million, 2010–15 34

LIST OF FIGURES
Figure 1: Europe biotechnology market value: $ million, 2006–10 10
Figure 2: Europe biotechnology market segmentation I:% share, by value, 2010 11
Figure 3: Europe biotechnology market segmentation II: % share, by value, 2010 12
Figure 4: Forces driving competition in the biotechnology market in Europe, 2010 13
Figure 5: Drivers of buyer power in the biotechnology market in Europe, 2010 14
Figure 6: Drivers of supplier power in the biotechnology market in Europe, 2010 15
Figure 7: Factors influencing the likelihood of new entrants in the biotechnology market in Europe, 2010 16
Figure 8: Factors influencing the threat of substitutes in the biotechnology market in Europe, 2010 17
Figure 9: Drivers of degree of rivalry in the biotechnology market in Europe, 2010 18
Figure 10: Astra Zeneca: revenues & profitability 22
Figure 11: Astra Zeneca: assets & liabilities 22
Figure 12: Boehringer Ingelheim : revenues & profitability 26
Figure 13: Boehringer Ingelheim : assets & liabilities 26
Figure 14: Merck KGaA: revenues & profitability 29
Figure 15: Merck KGaA: assets & liabilities 29
Figure 16: Novartis AG: revenues & profitability 32
Figure 17: Novartis AG: assets & liabilities 33
Figure 18: Europe biotechnology market value forecast: $ million, 2010–15 34


[Inhaltsverzeichnis ausblenden]